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Background: Several studies have demonstrated the importance of 
personality constructs on health behaviors and health status. Having 
a pessimistic outlook has been related to negative health behaviors 
and higher mortality. However, the construct has not been well 
explored in cancer populations. 
Methods: Survival time of 534 adults who were diagnosed with 
lung cancer was examined. The patients had completed the 
Minnesota Multiphasic Personality Inventory approximately 18.2 
years before receiving their lung cancer diagnosis. Minnesota 
Multiphasic Personality Inventory Optimism-Pessimism scores 
were divided into high (60 or more) and low scores (�60), and 
log-rank tests and Kaplan-Meier curves were used to determine 
survival differences. Multivariate Cox models were used for 
assessing prognostic values of pessimism along with other known 
predictors for lung cancer survival outcome. Bootstrapping of the 
survival models was used as a sensitivity analysis. 
Results: At the time of lung cancer diagnosis, patients were at an 
average age of 67 years old; 48% of them were women, 85% had 
non-small cell lung cancer, 15% had small cell lung cancer, 30% 
were stage I, 4% were stage II, 31% were stage III/limited, and 35% 
were stage IV/extensive. Patients who exhibited a nonpessimistic 
explanatory style survived approximately 6 months longer than 
patients classiﬁed as having a pessimistic explanatory style. 
Conclusion: Among lung cancer patients, those having a pessimistic 
explanatory style experienced a less favorable survival outcome, 
which may be related to cancer treatment decisions. Further research 
in this area is warranted. 
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“Mind-body” relationships have been revered since the time of Socrates. Personality or emotional factors may 
have a direct impact on physiological states or mind, which 
are evident in the current emphasis on stress reduction, 
relaxation, meditation, and activities related to disease pre­
vention and wellness promotion. Indeed, psychosocial factors 
may be predictive of poor disease outcome, including cancer 
survivorship. Pessimism and optimism are personality con­
structs that have been shown to be important in the general 
population and in some medical populations.1,2 Having a 
pessimistic explanatory style means the individual attributes 
bad events to internal, stable, and global causes; he or she 
tends toward self-blame, fatalism, and catastrophic thinking.3 
Recently, the role of having a pessimistic explanatory style 
has been explored in several cancer populations. For exam­
ple, Kung et al.4 found that having a pessimistic explanatory 
style was associated with poor quality of life in head and neck 
and thyroid cancer survivors; Petersen et al.5 found that a 
pessimistic explanatory style was predictive of poor quality 
of life in 268 breast cancer survivors. In contrast, optimism 
has also been associated with positive health outcomes in a 
number of studies; for instance, higher levels of optimism 
have been associated with lower blood pressure during daily 
life,6 better recovery from coronary artery bypass surgery,7 
and longer survival in patients with head and neck cancer.8 
However, such factors may be of little importance when the 
body experiences serious or fatal medical conditions, or 
potentially lethal diseases such as lung cancer. Using Selig­
man’s theory of causal attribution,3 the current retrospective 
study examined the relationship between a pessimistic ex­
planatory style and survival in a group of patients diagnosed 
with lung cancer. 
PATIENTS AND METHODS 
Study Design and Patients 
This study is a retrospective, observational cohort 
design aimed at examining the relationship between ex­
planatory style, as measured by scores on the Optimism-
Pessimism (PSM) scale of the Minnesota Multiphasic 
Personality Inventory (MMPI), and survival in patients 
diagnosed with lung cancer. Participants in this study were 
patients with primary lung cancer who were enrolled into 
the Epidemiology and Genetics of Lung Cancer Research 
Program at Mayo Clinic Rochester since 1997, in which all 
patients at Mayo Clinic who were diagnosed with lung 
Journal of Thoracic Oncology • Volume 5, Number 3, March 2010 326 
Journal of Thoracic Oncology • Volume 5, Number 3, March 2010 Pessimistic Explanatory Style for Lung Cancer 
cancer have been offered enrollment in a prospective 
cohort study.9 –12 All patients enrolled provided informed 
consent, and the study has been approved by the Institu­
tional Review Board. Trained study personnel reviewed 
the medical records; all patients completed health-related 
surveys when they entered the cohort study and again at 6 
and 12 months and were mailed similar surveys on an 
annual basis. Information on demographics, previous or 
concurrent illnesses, tobacco usage and exposure, tumor 
staging, nutritional habits, and cancer therapy were ab­
stracted and entered into the database. Comorbidities were 
combined into three variables for having any other lung 
disease, any other cancer, and any other disease. Having 
another lung disease included asthma, chronic bronchitis, 
emphysema, chronic obstructive pulmonary disease, pneu­
monia, tuberculosis, or cystic ﬁbrosis. Any other cancer 
was deﬁned as a cancer diagnosis except lung cancer. Any 
other disease was deﬁned as any disease except cancer or 
a lung disease; this category included diabetes, heart 
disease, arthritis, anemia, migraines, drug addiction, and 
any other medical problem. For a more detailed discussion 
of variable deﬁnitions, see Ref. 9. The Revised Staging 
System of non-small cell lung cancer (NSCLC) was 
used.14 All cancer treatment decisions were deferred to the 
individual patient’s healthcare providers, and enrollment 
into the research program did not in any way inﬂuence 
clinical decision making. This study used retrospective 
data from 534 individuals diagnosed with lung cancer who 
had completed the MMPI before receiving their lung 
cancer diagnosis. Medical records included information on 
age, sex, disease stage, smoking status, and survival status. 
If patients completed more than one MMPI, the PSM score 
from the earliest MMPI completed before lung cancer 
diagnosis was used to assess PSM. The MMPI was com­
pleted at the request of the patient’s physicians as part of 
the patient’s medical care or as a participant in a large 
research study. Patients who were asked to complete an 
MMPI were more likely among the most complex of 
referrals at our tertiary care medical center, because the 
physician making the request believed there were psycho­
logic factors intertwined with the presenting symptoms. 
Measures 
Smoking Status 
Patients who reported smoking fewer than 100 ciga­
rettes in their lifetime were classiﬁed as “never smokers.” 
Patients who had not smoked a cigarette in the past 30 days 
were classiﬁed as “former smokers,” and patients who re­
ported smoking any cigarette in the past 30 days were 
classiﬁed as “current smokers.”15 
The Minnesota Multiphasic Personality Inventory 
The original MMPI consisted of 550 unique true/ 
false items about thoughts, feelings, attitudes, physical 
symptoms, emotional symptoms, and previous life experi­
ences.16 The original MMPI and its current revision, the 
MMPI-2,17 have been the most widely used and thoroughly 
researched of the self-report measures of personality func­
tioning.18 All the analyses in the article were based on the 
original MMPI. 
The PSM scale for the MMPI was derived from 
Seligman’s theory of explanatory style19 and constructed 
from the items of the MMPI item pool.20 According to 
Seligman’s theory, the manner in which individuals ex­
plain the cause of signiﬁcant life events (both good and 
bad events) exerts considerable inﬂuence over three as­
pects of their future physical and mental health, which 
include decreased quality of physical health, increased 
risk for depression, and reduced occupational or aca­
demic achievement.21 More speciﬁcally, Seligman’s the­
ory postulates that people who (1) attribute the causes of 
adverse events in their lives to themselves (i.e., an interval 
explanation, “It’s me . . .”), (2) carry the expectation that 
the condition will persist (i.e., a stable explanation, 
“. . . happened again, as usual . . .”), and (3) that it will 
affect other aspects of their functioning (e.g., a global 
explanation, “. . . and now my life will be ruined; I’ll 
never get to . . .”) are at risk for undermining their subse­
quent physical health, emotional and mental functioning, 
and life achievement. 
The PSM scale yields normalized T-scores (mean � 
50, SD � 10). Lower PSM scores indicate having an 
optimistic explanatory style; whereas, higher scores indi­
cate a pessimistic explanatory style. Similar to previous 
research, PSM scores were divided into two groups for 
analysis: PSM scores representing the nonpessimistic (e.g., 
optimistic) patients were in the ﬁrst group (PSM scores of 
�60). Subjects with PSM scores of 60 or higher (1 SD 
above the mean) were considered to have a pessimistic 
explanatory style.4,5 Although this cut point has been used 
in other studies of pessimists,1,2,4 it is not based on a 
clinical cutoff score. We used recursive partitioning22 to 
determine the appropriateness of the score as our cut point 
when modeling survival times; the optimal cut point for 
our study cohort fell at 58, but we used a normalized score 
of 60 as being nearly optimal for the purpose of compa­
rability with published literature. 
Analyses 
PSM scores were divided into pessimistic explana­
tory style or nonpessimistic explanatory style, and t tests 
were used to determine demographic differences between 
patients highest and lowest in PSM scores. Log-rank tests 
and Kaplan-Meier curves were used to determine survival 
differences. Stepwise Cox proportional hazards models 
were used to model survival adjusting for age, gender, 
smoking status, cancer type, stage, and comorbidities. 
Variables were entered into the model one at a time. 
Modeling stopped when no other variables met the 0.05 
signiﬁcance level for entry into the model. Backward 
modeling (starting with a saturated model and dropping 
one variable at a time) was used to conﬁrm the results of 
the stepwise model. Martingale residuals were explored to 
determine the functional form of the PSM variable, and 
diagnostic checks were conducted to verify the ﬁt of the 
ﬁnal models. Bootstrapping of the survival analysis models 
was carried out as a sensitivity test of our ﬁndings by 
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TABLE 1. Selected Characteristics of Patients with Lung 
Cancer Who Completed the MMPI Before Being Diagnosed 
with Lung Cancer 
MMPIb No MMPIb 
Characteristicsa (N � 534) (N � 8786) 
Age at DXc 
Mean (SD) 67.4 (10.39) 65.7 (11.14) 
Stage 
I 147 (30) 1999 (23) 
II 21 (4) 589 (7) 
III/limited 152 (31) 2659 (31) 
IV/extensive 176 (36) 3310 (39) 
Cancer type 
SCLCd 72 (15) 933 (11) 
NSCLCe 424 (85) 7624 (89) 
Median time from diagnosis 14.8 mo 15.5 mo 
to last follow-up 
a Unless speciﬁed, number and percentage in parentheses are presented. 
b MMPI, Minnesota Multiphasic Personality Inventory; c DX, Diagnosis; d SCLC, 
small cell lung cancer; eNSCLC, non-small cell lung cancer. 
generating 10,000 random samples with replacement from 
our observed dataset.23 
RESULTS 
A total of 534 subjects had completed a MMPI 
before receiving their lung cancer diagnosis between 1997 
and 2006. Table 1 shows patients with and without a 
MMPI. There is no indication that patients with MMPI 
scores were clinically different on these characteristics 
than patients who did not complete a MMPI, and explan­
atory style is unlikely to have biased completion rates for 
the MMPIs among medical outpatients.24 Table 2 provides 
baseline demographics for the 534 patients who form the 
basis of this report. On average, patients had completed the 
MMPI 18.2 years before being diagnosed with lung cancer. 
Most patients had NSCLC (85%), and 34% of patients with 
NSCLC had early stage (I or II) lung cancer. In addition, 
most patients were current or former smokers (80%). None 
of the demographic variables were signiﬁcantly different 
between patients with a pessimistic explanatory style and 
patients with a nonpessimistic explanatory style. 
There were 110 patients who completed more than 
one MMPI before their lung cancer diagnosis. Of the 110 
patients with multiple MMPI scores, 12 (11%) went from 
being classiﬁed as pessimists to nonpessimists and 13 
(12%) changed from nonpessimists to pessimists. The 
median change for the patients was a decrease of one-half 
point on their PSM scores. We used the ﬁrst PSM score 
reported before lung cancer diagnosis to achieve a greater 
temporal span between the PSM score and cancer diagno­
sis. This minimizes the likelihood that a PSM score was 
affected by proximity to the personal stresses of receiving 
a diagnosis of lung cancer and the signiﬁcant symptoms of 
illness preceding the cancer diagnosis related to the cancer. 
TABLE 2. Characteristics of 534 Patients with Lung Cancer 
Who Completed a MMPI 
Nonpessimistic Pessimistic 
Explanatory Style Explanatory 
PSMd <60 Style PSMd >60 Total 
Characteristicsa (n � 304) (n � 230) (n � 534) 
Age at MMPIb 
Mean (SD) 48.4 (12.94) 49.9 (12.49) 49.0 (12.76) 
Median 49 51 50.0 
Range 14–97 15–78 14–97 
Age at DXc 
Mean (SD) 67.6 (11.10) 67.0 (9.40) 67.4 (10.39) 
Median 68.5 68.0 68 
Range 34–98 39–88 34–98 
Years From MMPIb 
to DX 
Mean (SD) 19.0 (10.08) 17.1 (9.38) 18.2 (9.82) 
Median 18.6 16.6 17.5 
Range 0.01–43.5 0.02–43.4 0.01–43.5 
Smoking status 
Missing 1 2 3 
Never smoker 48 (16) 21 (9) 69 (13) 
Former smoker 117 (39) 89 (39) 206 (39) 
Current smoker 117 (39) 103 (45) 220 (41) 
Current or former 21 (7) 15 (7) 36 (7) 
smoker 
Gender 
Female 149 (49) 108 (47) 257 (48) 
Male 155 (51) 122 (53) 277 (52) 
Cancer type 
SCLCe 37 (13) 35 (16) 72 (15) 
NSCLCf 243 (87) 181 (84) 424 (85) 
Stage 
Missing 24 14 38 
I 82 (28) 65 (30) 147 (30) 
II 10 (4) 11 (5) 21 (4) 
III/limited 94 (34) 58 (27) 152 (31) 
IV/extensive 94 (34) 82 (38) 176 (36) 
Any surgery 
Yes 123 (40) 75 (33) 198 (37) 
No 181 (60) 155 (67) 336 (63) 
Any chemotherapy 
Yes 85 (28) 62 (27) 147 (28) 
No 219 (72) 168 (73) 387 (72) 
Any radiation therapy 
Yes 69 (23) 40 (17) 109 (20) 
No 235 (77) 190 (83) 425 (80) 
Any other cancer 
Yes 32 (11) 34 (15) 66 (12) 
No 272 (89) 196 (85) 468 (88) 
Any other lung 
disease 
Yes 61 (20) 53 (23) 114 (21) 
No 243 (80) 177 (77) 420 (79) 
a Unless speciﬁed, number and percentage in parentheses are presented. 
b MMPI, Minnesota Multiphasic Personality Inventory; c DX, Diagnosis; 
d PSM, Optimism-Pessimism Scale Score; eSCLC, small cell lung cancer; f NSCLC, 
non-small cell lung cancer. 
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TABLE 3. Median Survival (mo) by PSM Groups 
95% Conﬁdence 
Interval 5-Year 
Log-Rank Survival 
Median Lower Upper p Rate 
Overall population 14.8 13.4 18.7 27.8% 
PSMa �60 19.2 14.8 23.5 0.0105 32.9% 
(nonpessimistic) 
60 � PSMa 13.1 10.9 14.8 21.1% 
(pessimistic) 
a PSM, Optimism-Pessimism Scale Score. 
FIGURE 1. Kaplan-Meier curve of survival time by PSM 
groups. Patients with a pessimistic explanatory style have 
shorter survival times than other patients. 
Pessimistic Explanatory Style and Survival 
Table 3 shows median survival times (in months) and 
the 5-year survival rate for all 534 patients and compares 
patients with low versus high scores on the PSM scale. 
Patients (both women and men) in the nonpessimistic 
category survived about 6 months longer compared with 
patients with a pessimistic explanatory style, as shown in 
the Kaplan-Meier curve in Figure 1. Five-year survival 
rates for the two groups were 32.9% for nonpessimists and 
21.1% for pessimists. 
The results from univariate Cox models are shown in 
Table 4. Stage of disease and treatment were highly 
correlated, i.e., 95% of patients with stage II cancer had 
surgery, 30% of patients with stage III had surgery, and 
only 6% of patients with stage IV had surgery. Because 
there was strong collinearity between stage and treatment, 
only treatment was used in the multivariate models along 
with other covariates. Results from the stepwise multivar­
iate model using pessimists versus nonpessimists are 
shown in Table 5, conﬁrming that patients with a pessi­
mistic explanatory style have signiﬁcantly worse survival 
rates even after adjusting for other known prognostic 
variables (hazard ratio � 1.25, p � 0.03). Having comor­
bidities seem to be associated with signiﬁcantly better 
survival (Table 4); however, the effects are confounded by 
TABLE 4. Univariate Cox Models for Survival 
95% Hazard 
Hazard Ratio Conﬁdence 
Variable p Ratio Limits 
Pessimist (60�) 0.0108 1.305 1.064 1.601 
Age at diagnosis �0.0001 1.022 1.012 1.033 
Male 0.0141 1.292 1.053 1.585 
Stage II 0.1500 0.655 0.368 1.165 
Stage III/limited 0.2087 1.155 0.923 1.445 
Stage IV/extensive �0.0001 4.134 3.305 5.171 
Former smoker 0.0452 0.805 0.651 0.995 
Current smoker 0.0045 1.346 1.097 1.653 
Current or former 0.0034 1.706 1.193 2.441 
smoker 
Chemotherapy 0.0058 1.365 1.094 1.703 
Radiation 0.0253 1.317 1.035 1.676 
Surgery �0.0001 0.234 0.182 0.300 
Other lung 0.2965 1.601 0.662 3.870 
treatment 
Any cancer 0.0675 0.748 0.549 1.021 
Any lung disease 0.0012 0.655 0.506 0.846 
Any other disease �0.0001 0.391 0.293 0.521 
TABLE 5. Multivariate Cox Model for Survival Including 
Pessimism, Treatment, and Comorbidities 
95% Hazard 
Ratio Conﬁdence 
Variable p Hazard Ratio Limits 
Pessimist (60�) 0.0339 1.25 1.02 1.55 
Age at diagnosis �0.0001 1.04 1.03 1.05 
Male 0.02 1.28 1.04 1.58 
Any surgery �0.0001 0.23 0.17 0.31 
Any radiation therapy 0.17 1.22 0.92 1.63 
Any chemotherapy 0.70 0.95 0.73 1.24 
Current smoker 0.0005 1.54 1.21 1.96 
Some smoking history 0.0005 2.02 1.36 3.01 
Any other cancer 0.35 1.18 0.83 1.66 
Any other lung disease 0.66 1.07 0.80 1.42 
age, smoking status, and treatment. In particular, patients 
with comorbidities were more likely to have surgery and 
more likely to be current smokers. Patients with other 
cancers were on average about 5 years older than patients 
without other cancers. After adjusting for these confound­
ing effects as presented in Table 5, the effects of comor­
bidities are no longer signiﬁcant. 
A stratiﬁed analysis was used to assess the relationship 
between pessimism and stage. Results suggest that having a 
pessimistic explanatory style is prognostic for survival in 
patients with stage I or II cancer but is not prognostic for 
patients with stage III or IV cancer. The observation was 
supported by a multivariate Cox model using only patients 
with stage I or II lung cancer (Table 6). After adjusting for 
demographics, comorbidities, and treatment, having a pes­
simistic explanatory style was still signiﬁcantly related to 
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TABLE 6. Multivariate Cox Model for Survival for Patients 
with Stage I or II Cancer 
95% Hazard 
Hazard Ratio Conﬁdence 
Variable p Ratio Limits 
Pessimist (60�) 0.02 1.91 1.10 3.29 
Age at diagnosis 0.001 1.06 1.02 1.10 
Male 0.17 1.47 0.85 2.53 
Any surgery 0.01 0.39 0.19 0.81 
Any radiation therapy 0.10 1.95 0.87 4.36 
Any chemotherapy 0.64 1.21 0.53 2.76 
Current smoker 0.03 1.87 1.06 3.31 
Some smoking 0.10 2.52 0.84 7.57 
history 
Any other cancer 0.33 0.72 0.38 1.38 
Any other lung 0.25 1.42 0.79 2.56 
disease 
shorter survival times (log-rank test p � 0.02, hazard 
ratio � 1.91). 
Several different sensitivity analyses provided results 
that were similar to the original analyses. A simulation 
involving 10,000 bootstrapped samples showed the robust­
ness of the results. Seventy-two percent of the bootstrapped 
samples resulted in signiﬁcant p values, with nonpessimists 
having longer survival times than pessimists. A small minor­
ity of samples (0.4% or 42 out of 10,000 samples) had results 
that showed pessimists having longer survival times, but 
the survival differences were not signiﬁcant in all of those 
samples. 
Another sensitivity analysis used the last MMPI score 
reported before diagnosis instead of the ﬁrst reported MMPI. 
In this analysis, the log-rank p value for differences in 
survival increased slightly and the difference in median 
survival decreased from 6.0 to 5.3 months. 
The relationship between depression (as measured by 
the MMPI, Scale 2, Depression) and survival was also ex­
plored, but there was no indication that depression was 
related to survival time (data not shown). 
DISCUSSION 
This retrospective study examined the relationship be­
tween survival and explanatory style using scores from the 
PSM scale of the MMPI. The major ﬁnding in the study was 
that explanatory style obtained from a large sample of pa­
tients diagnosed with lung cancer and measured (on average) 
18 years before receiving their lung cancer diagnosis, was 
statistically signiﬁcant and clinically relevant for survival. 
More speciﬁcally, patients classiﬁed as having an optimistic 
or a nonpessimistic explanatory style survived an average of 
6 months longer compared with the patients with a pessimis­
tic explanatory style. Furthermore, the relationship was inde­
pendent of smoking status, cancer stage, treatment, comor­
bidities, age, and gender. 
In examining stage of cancer, the prolonged survival 
time was only sustained among patients with stage I or II lung 
cancer, which indicates that if a patient has advanced disease, 
then the potentially protective aspect of a nonpessimistic 
explanatory style can be overwhelmed by the severity of the 
disease process. However, the results support the premise that 
if a patient is diagnosed with lung cancer, and if the patient 
has a pessimistic explanatory style, the patient may be less 
likely to have surgery and may live 6 months less compared 
with patients with a nonpessimistic style. This may be due to 
the overall risk for comorbid medical problems (i.e., as 
predicted by Seligman’s theory of pessimistic causal attribu­
tion), which in turn decreases the likelihood of receiving a 
surgical intervention. However, if a patient’s lung cancer was 
identiﬁed in the early stage, and if the patient has a nonpes­
simistic explanatory style, then the patient’s estimated sur­
vival is signiﬁcantly improved, in part, because surgical 
resection of the tumor can be completed as a curative treat­
ment. This 6-month potential beneﬁt related to an optimistic 
explanatory style is more impressive when one considers that 
the median survival time for this patient population with lung 
cancer is �1 year.9 
Seligman’s theory of explanatory style has been shown 
to be predictive of health status, mortality, health behaviors, 
and quality of life among general medical outpatients. The 
examination of a possible relationship between a pessimistic 
explanatory style and survivorship in oncology populations is 
a relatively new and provocative area of investigation. Such 
studies have yielded mixed results. Some suggest that having 
a pessimistic explanatory style before receiving a cancer 
diagnosis might be predictive of survival time and immune 
function; whereas, others have not found such an association. 
Rausch et al.25 found that higher levels of optimism were 
associated with improved immune function in women newly 
diagnosed with early stage breast cancer. Even in healthy 
subjects, researchers have found optimism to be associated 
with higher immune parameters, including higher T-lympho­
cyte numbers and natural killer cell activity.26,27 In a popu­
lation of black women coinfected with human immunodeﬁ­
ciency virus and human papillomavirus, Byrnes et al.28 found 
that women who were more optimistic had better immunity. 
Speciﬁcally, greater optimism was related to higher natural 
killer cell cytotoxicity and cytotoxic/suppressor cell numbers 
after controlling for presence/absence of human papilloma-
virus, behavioral/lifestyle factors, and subjective impact of 
negative life events. 
In a recent review article, Coyne et al.29 noted mixed 
results from studies (often ﬂawed by small samples and 
numerous potential confounders) examining broad person­
ality factors related to disease progression and mortality 
among patients with cancer. In summarizing the literature, 
Coyne et al. decry the lack of substantial support for 
widely held beliefs about the impact of personality factors, 
using a research model of their own large-scale work in 
head and neck cancers. Contrary to the view of Coyne et 
al., we deliberately chose not to use a broad measure of 
emotional well being. Rather, we used a theory-derived 
measure characterizing an enduring psychologic and cog­
nitive construct known as causal attribution. A summary of 
our approach follows: 
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Originally, Mayo Clinic researchers collaborated with 
Seligman and, using Seligman’s procedures for analyzing 
expository text, developed and published a bidirectional scale 
of PSM derived from the item pool of the original MMPI. 
Thus, Seligman’s theory of causal attribution was operation­
alized in the constructs of durable “pessimistic” and “opti­
mistic” personality traits. According to Seligman’s theory, 
individuals with a pessimistic explanatory style are at signif­
icant risk for later problems in three important areas of life 
functioning: (a) greater likelihood of adverse medical condi­
tions, (b) proneness toward mental health issues (particularly 
depression), and (c) reduced achievement (either occupa­
tional or academic). 
Seligman’s theory and the PSM scale have been vali­
dated among general medical outpatients. For example, a 
pessimistic explanatory style was signiﬁcantly associated 
with increased mortality among medical outpatients who 
completed the MMPI approximately 30 years before follow­
up.1 Overall, results from several previous studies30–34 have 
added considerable support to Seligman’s theory and the 
potentially adverse impact of having a pessimistic explana­
tory style. In general, we have found, as the theory predicts, 
patients classiﬁed as having a pessimistic explanatory style 
are at risk for poorer medical outcomes; whereas, being in the 
nonpessimist range of scores seems to be a psychologic 
protective factor. Seligman’s theory predicts that patients 
with lung cancer who were classiﬁed as having a pessimistic 
explanatory style would be at risk for gradually accruing 
adverse medical conditions over time, which may be related 
to the decreased likelihood of surgical treatment for patients 
in this explanatory category. Note: we are not implying a 
causal relationship between a pessimistic explanatory style 
and the development of lung cancer. 
Some limitations of the study should be considered 
when interpreting the results. First, the retrospective design of 
this study does not ensure that the measures were given at 
consistent times or to all possible participants. Patients who 
completed a MMPI might have exhibited behaviors or coping 
styles different from individuals who did not complete the 
MMPI; thereby, introducing selection bias into the study 
sample. Another potential source of bias relates to the mea­
surement of PSM at only one point in time. There is uncer­
tainty about whether a relationship existed between explan­
atory style and survival before diagnosis. A related limitation 
is that information was not available on cancer recurrence or 
comorbid medical conditions that may have occurred since 
the time of cancer diagnosis and could impact survival. 
Therefore, longitudinal studies are recommended to further 
investigate these possibilities. A ﬁnal limitation is the gener­
alizability of the results; the sample was primarily white and 
only consisted of patients diagnosed with lung cancer, there­
fore, the results may not apply to more diverse populations or 
other types of cancer. 
Despite the limitations, our study adds to the grow­
ing literature on explanatory style (e.g., PSM) and survival 
in the general population, in medical populations, and 
speciﬁcally in patients with lung cancer. Future investiga­
tions may beneﬁt from designing and testing interventions, 
which address enhancing positive aspects of explanatory 
style and evaluating the potential physiological mecha­
nisms responsible for increased survival. For example, 
patients diagnosed with cancer could learn cognitive be­
havioral techniques to challenge negative thinking patterns 
and engage in effective, accurate problem solving. This 
may ultimately aid in enhancing current approaches to 
patient care, such that clinicians may improve survival not 
only by developing new medical treatments but also by 
targeting patients’ psychosocial characteristics most likely 
to negatively affect cancer treatment decisions and ulti­
mate outcomes. 
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